Welcome to our dedicated page for Health In Tech SEC filings (Ticker: HIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health In Tech, Inc. (Nasdaq: HIT) files a range of reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed, Nevada-incorporated InsurTech platform company. Its SEC filings provide detailed information on financial performance, governance, equity plans, and material corporate events related to its AI-enabled healthcare and insurance marketplace.
On this page, you can review Health In Tech’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss revenues, operating expenses, cash flows, and segment-related data for its insurance technology platform. These filings also describe risk factors, business strategy, and the company’s focus on process simplification and automation for insurers, brokers, and TPAs.
Health In Tech’s current reports on Form 8-K document specific events such as earnings announcements, investor presentations, stockholder meetings, equity incentive plan amendments, restricted stock awards tied to new initiatives and programs, and changes in executive roles. For example, 8-K filings describe the company’s annual meeting voting results, grants of restricted stock for new initiatives, and terminations or appointments of certain officers.
Investors interested in ownership and governance can use proxy materials such as the DEF 14A definitive proxy statement to understand board elections, equity plan proposals, auditor ratification, and voting structures for Class A and Class B common stock. These documents outline how Health In Tech manages compensation, board composition, and stockholder rights.
Stock Titan enhances access to these filings with AI-powered summaries that explain key points from lengthy documents, helping users quickly interpret complex sections of 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new filings for HIT appear promptly, while structured views of forms such as 8-K and proxy statements make it easier to track developments in Health In Tech’s InsurTech operations, capital structure, and governance over time.
Health In Tech director William D. Howard acquired 128,474 shares of Class A Common Stock on June 23, 2025 at $0.62 per share through a restricted stock grant under the company's Equity Incentive Plan.
Key details of the restricted stock grant:
- Vesting conditions: Full vesting after one year of service from December 23, 2024
- Alternative partial vesting: At first shareholders' meeting based on service period ratio
- Vesting requirement: Continuous service through vesting date
- Total value of grant: Approximately $79,654
This Form 4 filing was signed by Howard on June 25, 2025, meeting the SEC's two-day reporting requirement for insider transactions. The shares are held directly by the reporting person.
Timothy Hayes, Director of Health In Tech (HIT), acquired 128,474 shares of Class A Common Stock on June 23, 2025, at a price of $0.62 per share through a restricted stock grant under the company's Equity Incentive Plan.
Key vesting terms:
- Full vesting after one year of service from December 23, 2024
- Alternative partial vesting at first shareholders' meeting based on service time ratio
- Vesting conditional on continuous service through vesting date
The transaction was reported via Form 4 filing on June 25, 2025, within the required reporting window. This equity grant aligns the director's interests with shareholders and serves as part of the company's executive compensation strategy.
Director Sanjay Shrestha of Health In Tech received a grant of 128,474 restricted shares of Class A Common Stock at $0.62 per share on June 23, 2025, as reported in this Form 4 filing.
Key details of the stock grant:
- Shares were granted under the Health in Tech Equity Incentive Plan
- Vesting conditions include: - Full vesting after one year of service from April 8, 2025, or - Partial vesting at first shareholders' meeting based on service period ratio
- Direct ownership form of securities
- Vesting subject to continuous service requirement
This equity grant appears to be part of director compensation and aligns the director's interests with shareholders through a one-year vesting schedule.
Director Chike Umemezia of Health In Tech received a grant of 128,474 restricted shares of Class A Common Stock on June 23, 2025, at a price of $0.62 per share under the company's Equity Incentive Plan.
The restricted shares have specific vesting conditions:
- Full vesting after one year of service from December 23, 2024, or
- Partial vesting at the first shareholders' meeting based on a pro-rata calculation of service time (up to 12 months) from December 23, 2024
The grant represents a direct ownership position and requires continuous service through the vesting date. This equity compensation aligns the director's interests with shareholders and serves as a retention mechanism through the vesting schedule.